Zevra Therapeutics (ZVRA) Common Equity (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Common Equity came in at $6000.0 in Q1 2026, down 99.99% YoY from $41.0 million in Q1 2025, and little changed on a QoQ basis from $6000.0 in Q4 2025.
Zevra Therapeutics (ZVRA) Common Equity (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Common Equity data on file, last reported at $6000.0 in Q1 2026.
- Quarterly Common Equity fell 99.99% year-over-year to $6000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6000.0 (down 99.99% YoY) and the FY2025 annual result came in at $6000.0, down 99.98% from the prior year.
- Common Equity was little changed at $6000.0 in Q1 2026, from $6000.0 in the prior quarter.
- In the past five years, Common Equity ranged from a high of $117.2 million in Q2 2025 to a low of -$16.7 million in Q3 2022.
- A 5-year average of $40.1 million and a median of $44.9 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity plunged 112.7% — and 2023, when it soared 886.45%.
- Tracing ZVRA's Common Equity over 5 years: stood at $75.1 million in 2022, then declined by 17.65% to $61.9 million in 2023, then slumped by 35.88% to $39.7 million in 2024, then sank by 99.98% to $6000.0 in 2025, then changed by 0.0% to $6000.0 in 2026.
- The last three Common Equity figures came in at $6000.0 (Q1 2026), $6000.0 (Q4 2025), and $6000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 217.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 217.65 Mn |
| Mar 31, 2026 | 6,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 117.23 Mn |
| Mar 31, 2025 | 41.02 Mn |
| Dec 31, 2024 | 39.67 Mn |
| Sep 30, 2024 | 69.77 Mn |
| Jun 30, 2024 | 32.48 Mn |
| Mar 31, 2024 | 48.82 Mn |
| Dec 31, 2023 | 61.86 Mn |
| Sep 30, 2023 | 61.52 Mn |
| Jun 30, 2023 | 58.87 Mn |
| Mar 31, 2023 | 59.27 Mn |
| Dec 31, 2022 | 75.12 Mn |
| Sep 30, 2022 | -16.74 Mn |
| Mar 31, 2022 | -7.54 Mn |
| Dec 31, 2021 | 101.66 Mn |
| Sep 30, 2021 | 131.74 Mn |
| Jun 30, 2021 | 130.66 Mn |